These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 19492974

  • 1. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R.
    J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
    [Abstract] [Full Text] [Related]

  • 2. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C, Wallin AK, Londos E, Minthon L.
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [Abstract] [Full Text] [Related]

  • 5. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [Abstract] [Full Text] [Related]

  • 6. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E, Onor ML, Saina M, Maso E.
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [Abstract] [Full Text] [Related]

  • 7. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 Nov; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 8. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [Abstract] [Full Text] [Related]

  • 9. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group.
    Alzheimer Dis Assoc Disord; 2006 Nov; 20(4):263-8. PubMed ID: 17132971
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D.
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.
    Arch Gerontol Geriatr Suppl; 2004 Oct; (9):297-307. PubMed ID: 15207427
    [Abstract] [Full Text] [Related]

  • 12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 13. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.
    Dement Geriatr Cogn Disord; 2005 Jul 31; 19(4):189-95. PubMed ID: 15677866
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun 31; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 15. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A, Upgrade Study Group.
    Curr Med Res Opin; 2005 Nov 31; 21(11):1809-18. PubMed ID: 16307702
    [Abstract] [Full Text] [Related]

  • 16. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN.
    Am J Geriatr Pharmacother; 2006 Jun 31; 4(2):154-60. PubMed ID: 16860262
    [Abstract] [Full Text] [Related]

  • 17. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
    Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, Kavanagh S.
    Int J Geriatr Psychiatry; 2009 May 31; 24(5):479-88. PubMed ID: 18985627
    [Abstract] [Full Text] [Related]

  • 18. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R.
    Int J Geriatr Psychiatry; 2004 Jan 31; 19(1):58-67. PubMed ID: 14716700
    [Abstract] [Full Text] [Related]

  • 19. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N.
    Acta Neurol Scand; 2009 Mar 31; 119(3):180-5. PubMed ID: 18759798
    [Abstract] [Full Text] [Related]

  • 20. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.
    J Alzheimers Dis; 2013 Mar 31; 35(2):349-61. PubMed ID: 23411693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.